Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Among authors: hulsmeyer m. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.
Schönfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hülsmeyer M, Brown N, Kaye PM, Schlehuber S, Hohlbaum AM, Skerra A. Schönfeld D, et al. Among authors: hulsmeyer m. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8198-203. doi: 10.1073/pnas.0813399106. Epub 2009 May 5. Proc Natl Acad Sci U S A. 2009. PMID: 19416843 Free PMC article.
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. Among authors: hulsmeyer m. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.
Hülsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A. Hülsmeyer M, et al. J Biol Chem. 2005 Jan 28;280(4):2972-80. doi: 10.1074/jbc.M411323200. Epub 2004 Nov 10. J Biol Chem. 2005. PMID: 15537658 Free article.
Dual, HLA-B27 subtype-dependent conformation of a self-peptide.
Hülsmeyer M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B. Hülsmeyer M, et al. J Exp Med. 2004 Jan 19;199(2):271-81. doi: 10.1084/jem.20031690. J Exp Med. 2004. PMID: 14734527 Free PMC article.
18 results